SequelSEC

CNS Pharmaceuticals, Inc. CNSP

Pharmaceutical Preparations · CIK 0001729427 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$15.99M
Fiscal year ended 2025-12-31
Free cash flow
-$13.83M
Fiscal year ended 2025-12-31

CNS Pharmaceuticals, Inc. (CNSP) reported net income of -$15.85M for the fiscal year ended 2025-12-31. This page shows 8 annual periods of income statement, balance sheet and cash flow figures normalized from CNS Pharmaceuticals, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

CNS Pharmaceuticals, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$15.99M-$14.90M-$18.87M-$15.27M-$14.49M-$9.45M-$3.83M-$881.79K
Net income-$15.85M-$14.86M-$18.85M-$15.27M-$14.50M-$9.46M-$3.88M-$7.39M
Research & development$9.77M$9.29M$14.10M$9.30M$9.81M$5.06M$1.85M$21.27K
Weighted-average diluted sharesUnavailableUnavailableUnavailableshares 1.36MUnavailableUnavailableUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$0$0$0$0$0$0
Diluted EPS$-35.75$-466.89$-12,509.11$-11.22$-16.50UnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$6.21M$5.61M$4.77M$5.97M$4.68M$4.39M$1.98M$860.52K
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

CNS Pharmaceuticals, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Cash & equivalents$7.20M$6.46M$548.72K$10.06M$5.00M$14.04M$7.24M$282.74K
Total assets$8.62M$8.70M$1.70M$13.05M$8.76M$15.85M$7.91M$683.33K
Current assets$8.10M$8.66M$1.59M$12.56M$7.48M$15.50M$7.89M$588.13K
Total liabilities$4.10M$2.52M$6.13M$4.92M$2.59M$1.91M$311.00K$1.23M
Current liabilities$4.10M$2.52M$6.13M$4.92M$2.59M$1.91M$311.00K$1.23M
Total equity incl. NCI$4.52M$6.18M-$4.43M$8.13M$6.16M$13.95M$7.60M-$549.30K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailable$3.68M$1.98M$946.33K$243.67K$128.07K

Cash flow

CNS Pharmaceuticals, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Operating cash flow-$13.81M-$17.11M-$14.14M-$10.56M-$13.54M-$7.32M-$3.55M-$716.38K
Capital expenditures$18.18K$4.19K$3.90K$4.42K$5.75K$17.94K$20.12K$0
Investing cash flow-$18.18K-$4.19K-$3.90K-$4.42K-$5.75K-$17.94K-$20.12K$0
Financing cash flow$14.57M$23.03M$4.64M$15.61M$4.51M$14.13M$10.26M$1.16M
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$187.73K$838.96K$1.01M$1.20M$1.72M$1.29M$477.10K$110.24K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

CNS Pharmaceuticals, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Free cash flow-$13.83M-$17.12M-$14.14M-$10.56M-$13.54MUnavailable-$3.57M-$716.38K
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio1.98x3.43x0.26x2.55x2.88x8.13x25.38x0.48x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open CNSP in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-31View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.